

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

BIOGEN INTERNATIONAL GMBH)	
And BIOGEN MA INC.,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. _____
)	
AMNEAL PHARMACEUTICALS LLC,)	
)	
Defendant.)	

**SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs hereby provide the information below with respect to the deadlines set forth in
21 U.S.C. § 355(j):

Date Patentee(s) Received Notice:	June 12, 2017
Date of Expiration of '376 Patent:	October 29, 2019
Date of Expiration of '999 Patent:	May 18, 2020
Date of Expiration of '001 Patent:	April 1, 2018
Date of Expiration of '840 Patent:	April 1, 2018
Date of Expiration of '514 Patent:	February 7, 2028
Hatch-Waxman Regulatory Exclusivity Deadline:	September 27, 2020

ASHBY & GEDDES

/s/ Steven J. Balick

Steven J. Balick (#2114)
Andrew C. Mayo (#5207)
500 Delaware Avenue, 8th Floor
P.O. Box 1150
Wilmington, DE 19899
(302) 654-1888
sbalick@ashby-geddes.com
amayo@ashby-geddes.com

Of Counsel:

James B. Monroe
Li Feng
Sanya Sukduang
Andrew E. Renison
Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Ave., N.W.
Washington, D.C. 20001
(202) 408-4000

*Attorneys for Plaintiffs Biogen International
GmbH and Biogen MA Inc.*

Dated: June 26, 2017